Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...

Altimmune ALT announced that the FDA has granted Breakthrough Therapy Designation to its lead pipeline candidate, pemvidutide ...

Rezdiffra FDA approval fuels sales; expansion to F4 MASH cirrhosis with 2027 trial data. Read more about MDGL stock here.

Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with ...

The key opportunities in the MASH treatment market include focusing on the drug segment, especially FGF21-based therapies, ...

Madrigal’s Rezdiffra tops $1B run-rate in MASH, but losses and rising GLP-1/FGF21 competition may cap upside into 2026. See ...